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Background: Chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME) is a relatively common and
potentially serious condition with a limited evidence base for treatment. Specialist treatment for paediatric CFS/ME
uses interventions recommended by National Institute for Health and Clinical Excellence (NICE) including cognitive
behavioural therapy, graded exercise therapy and activity management. The Lightning Process® (LP) is a
trademarked intervention derived from osteopathy, life-coaching and neuro-linguistic programming, delivered over
three consecutive days as group sessions. Although over 250 children with CFS/ME attend LP courses each year,
there are no reported studies on the effectiveness or cost-effectiveness.
Methods: This pragmatic randomised controlled trial is set within a specialist paediatric CFS/ME service in the
south west of England. Children and young people with CFS/ME (n = 80 to 112), aged 12 to 18 years old will be
randomised to specialist medical care (SMC) or SMC plus the LP. The primary outcome will be physical function
(SF-36 physical function short form) and fatigue (Chalder Fatigue Scale).
Discussion: This study will tell us whether adding the LP to SMC is effective and cost-effective compared to SMC
alone. This study will also provide detailed information on the implementation of the LP and SMC.
Trial registration: Current Controlled Trials ISRCTN81456207 (31 July 2012).
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The Royal College of Paediatrics and Child Health in the
UK has defined chronic fatigue syndrome or myalgic en-
cephalomyelitis (CFS/ME) as ‘generalised fatigue, causing
disruption of daily life, persisting after routine tests and
investigations have failed to identify an obvious underlying
“cause”’ [1]. The NICE guidelines recommend a minimum
time of three months of fatigue before making a diagnosis
in children [2].* Correspondence: Esther.crawley@bristol.ac.uk
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reproduction in any medium, provided the orCFS/ME in children is a relatively common [3-6] and
potentially serious condition with over 50% of children
bedbound at some stage and a mean time off school of
one academic year [7].
There is a limited evidence base for the treatment for
children with CFS/ME. There is one randomised controlled
trial (RCT) comparing cognitive behavioral therapy (CBT)
(n = 29) and waiting list (delayed CBT) (n = 33) which
reported improvements in fatigue, physical function and
return to full time school in the early CBT arm [8,9].
However, in this study, approximately 40% of those in
the early CBT arm did not have an improvement at five
months. In an RCT comparing family-focussed CBT versusl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were attending more school at discharge and three
months post treatment but not at the primary outcome
time point (6 months) [10]. Long-term follow-up (24
months) in this group showed that recovery (defined
using fatigue and school attendance) was 79% in the
family-focused CBT group compared with 64% in the
psycho-education group [11]. A recent RCT comparing
Internet based CBT (n = 68) with usual care (n = 67)
showed more children in the CBT arm (75% versus 16%)
attended full time school, did not have severe fatigue
and had normal physical functioning (78% versus 20%)
at six month follow-up [12].
The Phil Parker Lightning Process® (LP) is a trade-
marked intervention that is used for a variety of condi-
tions including CFS/ME. It has been developed from
osteopathy, life coaching and neuro-linguistic program-
ming. The intervention includes three group sessions on
consecutive days where young people are taught skills
that they can try out for themselves including looking at
their sitting and standing posture. Families currently pay
approximately £620 to attend the LP course.
Even though over 250 children and young people a
year use the LP as an intervention for their CFS/ME,
there are currently no reported studies investigating the
effectiveness or possible side effects (for example serious
adverse events) of the LP.
This trial continues from the SMILE feasibility study
which showed that recruitment, randomisation and data
collection on health resource use was feasible and accept-
able [13]. In this trial we will compare the effectiveness
and cost-effectiveness of specialist medical care (SMC)
plus the LP with SMC alone for children with CFS/ME.
Hypothesis
We will test the null hypothesis that the addition of the




This is a pragmatic [14] randomised controlled trial com-
paring SMC plus the LP with SMC alone among children
with CFS/ME. Qualitative research methods have been
integrated into this study to ensure clear understanding
of the processes (implementation, acceptability and set-
ting of the interventions). See Figure 1 for trial flow
diagram.
Population
Children and young people aged 12 to 18 years inclusive
will be recruited after assessment by the Bath/Bristol
paediatric CFS/ME service. This is a large regional and
national service that currently provides assessment andtreatment for over 250 children a year. The majority
of referrals are from South Gloucestershire, Bristol,
Somerset and West Wiltshire. Referrals are made by
paediatricians, general practitioners and, in some cases,
schools. Children are given a diagnosis of CFS/ME after
a thorough assessment and screening blood tests accord-
ing to guidelines produced by the National Institute for
Health and Care Excellence (NICE) [2]. The majority of
children referred into the service have CFS/ME as other
causes of fatigue are usually excluded prior to referral.
Approximately 10% of children referred into the service
are housebound and are assessed at home.
Inclusion/exclusion criteria
Children will be included if they have CFS/ME and are
between 12 and 18 years old inclusive. Children will be
excluded if: they are too severely affected to attend hos-
pital appointments (defined as children and young people
that do not regularly leave their house); or if they or their
parents have insufficient English to either understand the
patient information sheet and consent form to take part in
the LP or the research interviews.
Recruitment
Potentially eligible children and their families will be
identified by the clinician conducting the initial clinical
assessment who will inform them about the study and
give both the young person and their parents patient
information sheets. The clinician will obtain consent
from the young person and their family to be contacted
by a researcher. If willing, the recruiting researcher will
contact the family and arrange to visit them at a con-
venient location (usually at home) to discuss and pro-
vide further information about the study.
Randomisation
The recruiting researcher will explain the rationale for
the study and its design, the uncertainties about the ef-
fectiveness of either intervention, the known advantages/
disadvantages of the interventions, the options available
outside the RCT, and the right not to take part in the
study or to withdraw at any time. Willingness to partici-
pate will be ascertained, checking that both the young
person and their family understand the study. Those
willing to take part in the study will be asked to consent
to randomisation and sign the consent form. The recruit-
ing researcher will then telephone the automated random-
isation service operated by the Bristol Randomised Trials
Collaboration for the intervention allocation, which will
be conveyed to the participant. Allocation will be mini-
mised [15] by age and gender, and retain a random com-
ponent to reduce risk of prediction of allocation. If for any
reason the service is unobtainable, randomisation will be
Figure 1 SMILE flow diagram.
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pant will be told of the results by phone or in person.
Interventions
 SMC: children and their families are offered a
variety of treatment options that are recommended
in NICE guidelines [2]. Typically this is centred
around graded activity and involves a follow-upphone call at two weeks followed by family based
rehabilitation consultations lasting one hour at
approximately six weeks, three months, and four
and a half months. The number and timing of the
sessions are agreed with the child and family and
varies depending on the needs and goals of the
child. Children who have high levels of anxiety are
offered three individual sessions of CBT every two
weeks over a six week period. Other interventions
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available for children and young people if needed.
The clinical team providing SMC are not informed
by the research team to which trial arm a participant
has been allocated.
 SMC plus the LP: in addition to the SMC detailed
above, young people and their parents will be asked
to read the information about the LP on the website
[http://www.lightningprocess.com] or using
information sheets. If the young person is well
enough, they will be asked to read a book about the
LP, given to them from the LP team, or listen to an
audio book if preferable. Children/young people and
their parents will be asked to complete an
assessment form (which will take about ten minutes)
where they are asked to identify their goals and
describe what they learnt from reading the book.
After this they will have a telephone call with a LP
practitioner (usually approximately 20 minutes).
This is used to check that the young person and
their parents are happy about attending the
course, checks the goals identified by the young
person and is an opportunity for the young person
and their parents to ask further questions. If the
young person and their family are happy to
continue, the young person will be given a date to
attend a course.
 The course is three sessions on three consecutive
days. Each session is three hours and forty-five minutes
long. Group sessions will include three to five young
people between 12 and 18 years of age who live within
the region covered by the CFS/ME service. During the
group, children and young people will receive a theory
session and a practical session. The course is free to
those participating in the trial.
1. The theory session will include taught elements
on the stress response, how the mind-body inter-
acts and how thought processes can be both help-
ful and negative. The language used by young
people will be discussed and in some cases chal-
lenged. Young people will be encouraged to think
about what they may be able to take responsibility
for and change. The taught sessions are followed
by a group discussion.
2. The practical session is used to put some of the
skills learnt into practice. Young people identify a
goal they wish to achieve (such as standing for
longer) and are then given alternative ways to
think about and prepare for this. This involves
using different cognitive (thinking) strategies
before and during the period in which achieving
the goal is attempted. Young people are also
asked to identify a goal wherein they can practise
the strategies in the afternoon or evening. Thisgoal will usually be short but could be an activity
that is up to 30 minutes long.
3. The LP practitioner will then arrange two follow-
up phone calls with the young person and parents
within two weeks of the course and then
approximately six to eight weeks later.‘Outcome assessment’
The following self-completed inventories will be collected
at the first clinical assessment (baseline), 3, 6 and 12
months: 11 item Chalder Fatigue Scale [17]; pain visual
analogue scale; physical function short form (SF-36)
[18]; the Spence Children’s Anxiety Scale (SCAS) [19];
the Hospital Anxiety and Depression Scale (HADS) [20]
for children aged 14 and over, and the Euroqol (EQ-5D)
[21] a five-item quality of life inventory. Children and
young people are asked about school attendance and
home tuition in a two-item inventory. We will ask for
consent to check school attendance using school records
at assessment, 3, 6 and 12 months. Follow-up question-
naires will be sent in the post with a stamped addressed
envelope for self completion.
Primary outcome
The primary outcome will be the SF-36 physical func-
tion subscale analysed as a continuous variable collected
at six months post-randomisation. The SF-36 will be
scored as the sum of responses to the ten items, each
of which is coded 0 for ‘Yes, limited a lot’, 5 for ‘Yes,
limited a little’ and 10 for ‘No, not limited at all’. This
yields a score varying from 0 (for the highest level of
disability) to 100 for no disability. The SF-36 physical
function subscale will be used as we are primarily inter-
ested in change in physical function. It has been used
in studies of adolescent CFS/ME [22] and in CFS trials
in adults [16]. We chose six months as this was the first
time that all those randomised to LP and SMC will
have received LP. Secondary outcome measures will be
school attendance, calculated as a percentage of expected
sessions, at 3, 6 and 12 months; the SF-36 (physical func-
tion) at 3 and 12 months; the Chalder Fatigue Scale score
at 3, 6 and 12 months; pain visual analogue scale at 6
months and quality adjusted life years (QALYs, derived
from the EQ-5D) over the 12 month follow- up period.
Measures used for economic evaluation
Parent(s)/guardian(s) will be asked to complete three
inventories at the start of the trial (just after random-
isation) and at 3, 6 and 12 months. These include an
adapted four-item Work Productivity and Activity Impair-
ment Questionnaire: General Health V2.0 (WPAI:GH)
[23] and a resource use questionnaire assessing health
service (for example, GP or specialist care), educational
service (for example, school counsellor) use and travel
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included in Additional file 1 and Additional file 2).
Non-responders
Those who have not replied within one week of each mail
out will be sent a reminder letter requesting that the
original set of questionnaires is completed and returned.
A reduced set of questionnaires (comprising SF-36, Chalder
Fatigue Scale score and school attendance inventory)
with a stamped addressed envelope will also be included
in case the originals have been mislaid. After another
two weeks, those not returning any questionnaires will
be telephoned by a researcher who will invite the respond-




We used a definition of a clinically important difference
for the SF-36 physical function subscale from three ex-
pert consensus panels for chronic diseases in adults. The
panels conducted a literature search and used the Delphi
technique to reach consensus on the thresholds for change
over time for small, moderate and large clinically important
SF-36 change scores [24]. Consensus was agreed by each
panel that a small clinically important difference would
be 10 as this is the equivalent to two state changes (a
state change is one improvement in one item - the mini-
mum difference between inventories). A moderate improve-
ment was defined as 20 and a large improvement as 30.
To be able to detect a difference between the two
treatment arms of 8 to 10 points on the SF-36 PCS at
six months with 90% power and 1% two-sided alpha, we
have calculated (using STATA) that a total of 32 to 50
participants in each arm for analysis are required. Allow-
ing for 10 to 20% non collection of primary outcome
data at six months, we aim to recruit 80 to 112 partici-
pants to the study.
Data analysis
The analysis and presentation of the trial will be in ac-
cordance with CONSORT guidelines [14]. A full statis-
tical analysis plan will be developed and agreed with the
Trial Management Group and Trial Steering Committee
prior to conducting any analyses.
We will use descriptive statistics to compare character-
istics of invited individuals who did or did not agree to
take part and eligible individuals who were randomised
or not randomised. We will also examine the balance
between the trial arms in participant characteristics.
The primary intention-to-treat analysis will compare
the SF-36 physical function subscale at six months be-
tween groups using multivariable linear regression adjust-
ing for baseline value of the outcome and minimisationvariables, paying attention to 95% confidence intervals as
well as P-values. Similar analyses using appropriate regres-
sion models will be conducted for secondary outcomes.
Sensitivity analyses will be conducted using standard tech-
niques to impute missing data [25], and to estimate the
efficacy of the intervention among compliers.
The statistical analysis plan including subgroup ana-
lyses for the primary outcome. This will be conducted to
explore differences in outcome according to age (< 14.99
versus 15.0 to 17.99), gender (male/female) and severity
(no school attendance versus some school attendance)
as age and gender are risk factors for CFS/ME and disease
severity is a predictor of outcome. These subgroup ana-
lyses are exploratory and will be interpreted with due
caution [26]. Any suggestion that the intervention effect
differs according to age, gender or severity would need
to be confirmed in subsequent studies. These will in-
clude interaction terms in regression models.
Economic evaluation
The economic evaluation will gather information on the
costs to the NHS, other government agencies and wider
society of the interventions in the two arms of the RCT.
The primary cost-effectiveness analysis will compare
incremental differences in NHS (including LP referral
costs) and other public sector costs with any health gains
achieved over 12 months, measured in QALYs. We will
estimate the net monetary benefit of specialist medical
care plus the LP compared to specialist medical care alone
and quantify uncertainty using confidence intervals, cost-
effectiveness acceptability curves and sensitivity analyses
[27]. In secondary analyses we will tabulate the wider
costs, including travel and productivity costs and conse-
quences, including school time missed, in a cost conse-
quence study [28,29].
Qualitative research
A process evaluation, drawing on qualitative research
methods, will be undertaken to assess the implementa-
tion, acceptability and setting of the intervention as well
as to explore users’ and practitioners’ views and experi-
ences of both the intervention and outcomes.
In-depth interviews
Interviews with parents and children/young people were
conducted at three time points for the feasibility study:
after initial assessment but prior to randomisation, after
randomisation but prior to the intervention and after
the intervention. Analyses of data will continue from the
feasibility study, supplemented with further in-depth in-
terviews undertaken with some parents and children after
the intervention to further assess their experiences of the
trial and intervention. Interviews will be semi-structured
in that they will follow a checklist of topics to ensure
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issues of importance. Interviews will explore the recruit-
ment process, including views and experiences of the
initial assessment and recruitment to trial appointments,
the written and verbal information provided to potential
participants and its acceptability, and reasons for accept-
ing or declining participation; beliefs, expectations and
preferences about interventions in the early stages of the
trial, and experiences of interventions and outcome later
on; and prior exposure and external influences to the
intervention that might impact upon its implementation
and effectiveness.
Recording of recruitment to trial consultations
All recruitment consultations will be audio-recorded to
document the interaction between recruiter and poten-
tial participant to explore information provision, re-
cruitment techniques, patient treatment preferences,
and randomisation decisions to identify recruitment dif-
ficulties and support change. This novel method can
provide essential information about the way the study
and its interventions are perceived as well as optimising
methods for recruitment and design. It has proved crucial
in evaluating information exchange and improving in-
formed consent and rates of randomisation/acceptance
of allocation in previous studies [30-32].
Observations
We will analyse observation data already collected on a
small number of interventions, specialist medical assess-
ments and specialist medical treatment follow-up sessions
observed by the qualitative researcher to assess the im-
plementation, acceptability and setting of intervention/
treatment provision. Detailed notes have been taken, in-
cluding the context, intensity and variability of intervention/
treatment delivery, to understand how intervention/
treatment is delivered and received in practice and to
help interpret outcome results (for example, variations
of effects in subgroups). All intervention sessions were
audio-recorded, with consent, for monitoring purposes.
We may observe further sessions if necessary following
analysis of existing data. The final number of observa-
tions will be determined by data saturation, although up
to ten observations in total are anticipated.
Qualitative data analysis
Analysis will be an ongoing and iterative process com-
mencing soon after data collection. It will build on data
analysed from the feasibility study and will inform fur-
ther sampling and data collection. Interview transcripts
and observation notes will be imported into NVivo (QSR
International) [http://www.qsrinternational.com/products_
nvivo.aspx: 2011] where they will be systematically assigned
codes and analysed thematically to identify themes usingtechniques of constant comparison. Individuals exhibiting
contrasting attitudes (‘negative cases’) will be studied in
detail to understand reasons underlying such contrasts
and to gain a deeper understanding of the data and find-
ings. Throughout analysis, the perspectives of the indi-
viduals will be paramount, with careful account taken
of the context within which the discussion takes place.
Descriptive accounts will be produced, and theoretical
explanations for behaviours, opinions and decisions will
be developed.
Content analytic methods will be used to describe in a
structured manner what was said by whom and how
often in the consent to randomisation appointments. More
flexible grounded theory methods (as in the interviews
above) will be applied to identify common or divergent
themes, particularly focussing on the impact of state-
ments by the recruiter on patients. Conversation ana-
lysis will be used to focus in great detail on certain
sections of the transcripts, for example the interactions
during which randomisation is offered.
Data protection
Children and young people are allocated a unique 13
digit identification number made up of the centre num-
ber, the team number, an individual patient number, first
four digits of the postcode, and patient initials. This
number is assigned to the patient and is used on assess-
ment forms prior to transfer of data so they are anon-
ymised at source. A list of names and corresponding
identification numbers are kept separately and securely
on a password protected NHS server.
Audio-recordings will be encrypted, password protected
and stored on a secure university server for five years. This
is to enable us to check recordings if necessary while re-
ports are being written. Transcripts will be anonymised
and secure password protected university server.
Data monitoring
The data monitoring group will receive notice of serious
adverse events (SAEs) for the sample as whole. If the in-
cidence of SAEs of a similar type is greater than would
be expected in this population, it will be possible for the
data monitoring group to receive data according to trial
arm to determine any evidence of excess in either arm.
Primary outcome data at six months will be examined
once data are available from 50 patients, to ensure that
neither arm is having a detrimental effect on the majority
of patients. An independent statistician with no other
involvement in the study will investigate whether more
than 20 participants in the study sample as a whole have
experienced a reduction of ≥ 30 points on the SF-36 at
six months. In this case, the data will then be summarised
separately by trial arm, and sent to the data monitoring
group for review. This process will ensure that the trial
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by treatment arm.Ethical review
A favourable ethical opinion was given on 8 September
2010 (reference 10/H0206/32) by South West 2 Local Re-
search Ethics Committee. Two favourable opinions have
been provided on 31 May 2011 and 6 September 2012 for
amendments to study documents and protocol.
All children, young people and parents/carers involved
in the study provided consent or assent (under 16 years).
Parents of children providing assent also provided con-
sent to take part in the study.Discussion
Paediatric CFS/ME is a relatively common and frequently
disabling condition with limited treatment options of
proven efficacy available within the NHS. Although the
LP is popular, it currently has anecdotal evidence to
support its efficacy as no formal studies have as yet been
carried out. It is important for parents, children with
CFS/ME and the NHS to know whether the LP is more
effective and cost-effective when used with NHS SMC
rather than existing NHS SMC alone.
CFS/ME is different in children and adults with different
risk factors [33-35], course and outcome [36]. It is there-
fore not possible to complete a study in adults and ex-
trapolate the results to children. Children and families will
also be followed-up closely during and after the LP inter-
vention. The interviews with parents at different stages
of the study will help us understand parental and young
people’s views at each stage of the process.
Because the participants will be young people, we have
put in place rigorous procedures for informed consent
from young people and their parent(s)/guardian(s) if they
are < 16 years old. In the clinic, the clinician will ask for
consent/assent for contact by a researcher and qualitative
researcher. Consent/assent to the study and to random-
isation will be obtained by a researcher after a full explan-
ation of the study when both the young person and the
family have had sufficient opportunity to ask questions.
Young people and their families will be given as long as
they need before giving consent/assent within the confines
of the study. We will then obtain further consent/assent
prior to each interview to check that young people or their
parents continue to be willing to participate. We will also
obtain consent/assent prior to recording any interventions
from all present.
Qualitative data collected to date demonstrate that both
children and their families find the recruitment process
acceptable, the information given of high quality and both
children and their parents have been grateful they were
part of the study.Trial status
On going trial.
Additional files
Additional file 1: Work Productivity and Activity Impairment
Questionnaire: General Health V2.0.
Additional file 2: Example of Health Resource use questionnaire.
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